Identification and management of patients at high bleeding risk undergoing percutaneous
coronary intervention are of major importance, but a lack of standardization in defining this …

Overwhelming evidence shows the quality of reporting of randomised controlled trials
(RCTs) is not optimal. Without transparent reporting, readers cannot judge the reliability and …

Advances in antithrombotic therapy, along with an early invasive strategy, have reduced the
incidence of recurrent ischemic events and death in patients with acute coronary syndromes …

ESC Guidelines 3002 recommendations. To implement the guidelines, condensed pocket
guidelines versions, summary slides, booklets with essential messages, and an electronic …

Aim After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events,
despite contemporary treatment, including aspirin and clopidogrel. We evaluated the safety …

The activated serine protease factor Xa is a promising target for new anticoagulants. After
studies on naturally occurring factor Xa inhibitors indicated that such agents could be …

Thromboembolism involving the arterial or venous circu-lation or arising from the heart is a
common cause of morbidity and mortality. Rapidly acting parenteral anticoagulants, such as …

This article focuses on new antithrombotic drugs that are in or are entering phase 3 clinical
testing. Development of these new agents was prompted by the limitations of existing …

Chronic kidney disease (CKD) is a pandemic public health problem, with 500 million people
worldwide estimated to have some form of kidney injury. 1 Survey data suggest that the …

Thrombosis is the underlying cause of a host of common, debilitating, and often fatal
cardiovascular disorders. Formation of thrombi in the arterial circulation can lead to acute …